Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poly ICLC - Oncovir

Drug Profile

Poly ICLC - Oncovir

Alternative Names: Hiltonol; P.I.C.L.C.; Poly-ICLC; Polyinosinic polycytidylic acid; polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose; Polyriboinosinic-polyribocytidylic acid

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical University of South Carolina; Oncovir
  • Developer Abramson Cancer Center of the University of Pennsylvania; Augusta University; Icahn School of Medicine at Mount Sinai; immatics biotechnologies GmbH; Ludwig Institute for Cancer Research; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); New York University School of Medicine; Oncovir; Quest PharmaTech; Roswell Park Cancer Institute; University Hospitals of Geneva; University of California, San Diego; University of Pittsburgh; Washington University School of Medicine
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Proto oncogene protein c rel modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer; Flavivirus infections; Orthopoxvirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Ovarian cancer; Solid tumours
  • Phase I/II B-cell lymphoma; Colorectal cancer; Glioblastoma; HIV infections
  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Glioma; Myelodysplastic syndromes; Prostate cancer
  • No development reported Anaplastic astrocytoma; Cytomegalovirus infections; Influenza virus infections; Pancreatic cancer; Smallpox

Most Recent Events

  • 02 Jan 2019 Icahn School of Medicine at Mount Sinai plans a phase I/II trial for Non-hodgkin's lymphoma, Breast cancer, and Head and neck cancer (Combination therapy) in USA (NCT03789097)
  • 28 Dec 2018 No recent reports of development identified for phase-0 development in Glioblastoma(Newly diagnosed) in USA
  • 25 Sep 2018 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable) in USA (IM) (NCT03721679)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top